EXOZYMES INC.
No SEC Form 4 filings for $EXOZ in the last 30 days.
See all $EXOZ insider activity →eXoZymes Inc. (NASDAQ:EXOZ) reported Q2 2026 results, highlighting a 10-fold increase in manufacturing productivity for its lead NCT program, a $6 million public offering, and a $2 million NIH grant. The company reported a net loss of $2.88 million for the quarter and $5.65 million in cash. Management will discuss these results and business updates in a webinar today.
eXoZymes Inc. (NASDAQ:EXOZ) announced a 10-fold productivity increase in its NCT manufacturing process, reducing reaction time by 80% and boosting output per liter by 67%. The company's internal assessments show a 100x reduction in estimated manufacturing costs from the first to the current process. These improvements support scalable commercial production and technology transfer to future partners, according to eXoZymes.
According to eXoZymes Inc.’s Aug. 20, 2026 SEC 10-Q, its net loss widened 24.5% year over year to $5.25 million, mainly due to higher R&D costs and lower grant funding. The company said June 2026 equity offerings raised $5.86 million, improving liquidity, but it reported substantial going-concern doubt due to insufficient working capital.
Over the past 7 days, alphai's AI scored 2 news stories mentioning EXOZ (EXOZYMES INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent EXOZ coverage spans corporate actions, earnings and technology.
Quarterly earnings and financing update may affect short-term price volatility.
The release is a positive manufacturing-readiness signal that could improve partner interest and future commercialization economics, but it is not yet a confirmed commercial contract or financial guidance.
Liquidity improved via equity proceeds, but working-capital insufficiency keeps going-concern risk elevated.
The filing highlights continued operating losses, no revenue, and a liquidity/going-concern warning alongside new equity funding and R&D expansion.
DOE-funded digital-twin work expands eXoZymes’ AI strategy into AI-guided manufacturing, adding a near-term funded R&D catalyst.
alphai scores every news story that mentions EXOZ with an AI model for sentiment and relevance, and aggregates insider trades from EXOZYMES INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
eXoZymes Inc. (NASDAQ:EXOZ) reported Q2 2026 results, highlighting a 10-fold increase in manufacturing productivity for its lead NCT program, a $6 million public offering, and a $2 million NIH grant. The company reported a net loss of $2.88 million for the quarter and $5.65 million in cash. Management will discuss these results and business updates in a webinar today.
2 min readeXoZymes Inc. (NASDAQ:EXOZ) announced a 10-fold productivity increase in its NCT manufacturing process, reducing reaction time by 80% and boosting output per liter by 67%. The company's internal assessments show a 100x reduction in estimated manufacturing costs from the first to the current process. These improvements support scalable commercial production and technology transfer to future partners, according to eXoZymes.
4 min readAccording to eXoZymes Inc.’s Aug. 20, 2026 SEC 10-Q, its net loss widened 24.5% year over year to $5.25 million, mainly due to higher R&D costs and lower grant funding. The company said June 2026 equity offerings raised $5.86 million, improving liquidity, but it reported substantial going-concern doubt due to insufficient working capital.
1 min readExoZymes Inc. (EXOZ) reported 2Q 2026 and six months ended June 30, 2026 results with $0 revenue. The six-month net loss was $5.25M, wider than the prior-year period. The company cited increased R&D spending, NIH BioClick and a $3M NSF CFIRE portion, and June 2026 equity financings, while disclosing substantial doubt about 12-month runway.
1 min readeXoZymes Inc. (NASDAQ:EXOZ) said it was selected for the U.S. Department of Energy Genesis Mission with Lawrence Berkeley National Laboratory to build AI-powered digital twins for cell-free biomanufacturing. The 9-month project is funded at about $747,000 total, including $147,000 for eXoZymes, and includes access to DOE AI and HPC resources.
4 min readEXOZYMES INC. (EXOZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 ex10-1.htm EX-10.1 Exhibit 10.1 PLACEMENT AGENT AGREEMENT Public Ventures LLC 14135 Midway Road, Suite G-150 Addison, Texas 75001 Attention: Anthony DiGiandomenico, Head of New Venture Discovery June 30, 2026 Ladies and Gentlemen: This letter (this “Agreement”) constitu
4 min readEXOZYMES INC. (EXOZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0002010788 0002010788 2026-06-17 2026-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
2 min readEXOZYMES INC. (EXOZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.2 4 ex10-2.htm EX-10.2 Exhibit 10.2 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “ Warrant Agreement ”) dated as of June 5, 2026 (the “ Issuance Date ”) between eXoZymes Inc., a company incorporated under the laws of the State of Nevada (the “ Company ”), and VStoc
3 min read
